pISSN 2234-3806eISSN 2234-3814
Table. 2.
Demographic and clinical characteristics of patients with MOGAD and seropositive NMOSD
| Variable | MOGAD | Seropositive NMOSD (N=66) | ||||
|---|---|---|---|---|---|---|
| NMOSD phenotype (N=17) |
ON phenotype (N=13) | Other (N=9) | Total (N=39) | |||
| Age at onset, yrs | 31.4±15.4 | 42.1±18.5 | 27.9±12.7 | 34.2±16.6 | 39.6±15.7 | 0.105 |
| Female, N (%) | 10 (58.9) | 7 (53.8) | 5 (55.6) | 22 (56.4) | 59 (89.4) | <0.001 |
| Disease duration, yrs | 2.6±3.1 | 0.6±0.8 | 6.5±7.4 | 2.8±4.5 | 7.0±7.1 | <0.001 |
| Relapse number | 3.5±2.2 | 1.9±1.3 | 3.4±3.2 | 3.0±2.3 | 4.0±5.0 | 0.618 |
| Onset of clinical syndrome, N (%) | 0.007 | |||||
| ON | 11 (64.7) | 13 (100) | 0 | 24 (61.5) | 22 (35.5) | |
| TM | 4 (23.5) | 0 | 2 (22.2) | 6 (15.4) | 22 (35.5) | |
| Brain or BS encephalitis | 2 (11.8) | 0 | 6 (66.6) | 8 (20.6) | 8 (12.9) | |
| Poly-regional onset | 0 | 0 | 1 (11.1) | 1 (2.5) | 10 (16.1) | |
*One case showing double positivity for MOG-Abs and AQP4-Abs was included.
†
Abbreviations: MOGAD, myelin oligodendrocyte glycoprotein autoantibody-associated disease; NMOSD, neuromyelitis optica spectrum disorder; ON, optic neuritis; TM, transverse myelitis; BS, brainstem; MOG-Ab, myelin oligodendrocyte glycoprotein autoantibody; AQP4-Ab, aquaporin-4 antibody.
Ann Lab Med 2024;44:56~63 https://doi.org/10.3343/alm.2024.44.1.56
© Ann Lab Med